Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohnʼs Disease

Stein, Ronen; Lee, Dale; Leonard, Mary B.; Thayu, Meena; Denson, Lee A.; Chuang, Emil; Herskovitz, Rita; Kerbowski, T.; Baldassano, Robert N.

doi:10.1097/mib.0000000000000769

Cited by 38 publications

(37 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to tissue TNF‐α, serum TNF‐α is convenient to measure and can be performed on the same samples used to measure the serum anti‐TNF‐α agent levels. Stein et al . recently published an investigation of serum IFX, anti‐IFX antibody, and serum TNF‐α in pediatric patients with CD.…”

Section: Discussionmentioning

confidence: 99%

“…32,33 In contrast to tissue TNF-α, serum TNF-α is convenient to measure and can be performed on the same samples used to measure the serum anti-TNF-α agent levels. Stein et al 34 recently published an investigation of serum IFX, anti-IFX antibody, and serum TNF-α in pediatric patients with CD. They demonstrated that a decrease in serum TNF-α levels from baseline is a predictive factor for continuing IFX therapy at 12 months.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease

Sugita

Watanabe

Kamata

et al. 2018

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease

Sugita

Watanabe

Kamata

et al. 2018

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…112 In pediatric Crohn's disease, higher concentrations of infliximab during the induction phase predict a sustained response to the drug. 113 Combination therapy: immunomodulators and anti-TNF Immunomodulators such as azathioprine/6-mercaptopurine and methotrexate have recently been used in an attempt to restore response to an anti-TNF agent once the patient has developed antibodies against the drug (n=5, young adults). 114 In a retrospective review of the PIBD Collaborative Research Group Registry, infliximab plus an immunomodulator was found to increase the chance that the patient would benefit from infliximab for five years (n=502).…”

Section: Biologicsmentioning

confidence: 99%

Diagnosis and management of inflammatory bowel disease in children

Oliveira

Monteiro

2017

BMJ

123

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are lifelong conditions that often begin in childhood. The implications of IBD are of particular importance in children because of the potential negative effects on growth, development, psychosocial function, and overall wellbeing. The key management strategy is to achieve sustained control of intestinal inflammation and monitor for potential complications of the disease and side effects of therapies. Overall, the evidence on the management of IBD in children is less extensive than in adults, but good quality multicenter studies and various guidelines and society consensus statements are available. This review summarizes the evidence on the pathophysiology, diagnosis, and approaches to management of children and adolescents with IBD.

show abstract

“…The value of albumin, haemoglobin and CRP for predicting anti‐TNF response has been reported in several studies (Table S7). Evidence from one study suggests that baseline neutrophil‐to‐lymphocyte ratio predicts secondary loss of response to IFX treatment in UC patients (HR 3.86 [1.20‐12.4], P = 0.023; AUC 0.798) …”

Section: Resultsmentioning

confidence: 99%

Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease—personalised medicine in its infancy

Stevens

Matheeuwsen

Lönnkvist

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Inflammatory bowel disease (IBD) is characterised by substantial heterogeneity in treatment response. With an expanding number of therapeutic agents, identifying optimal treatment at the patient level remains a major challenge. Aim To systematically review the available literature on predictive biomarkers of therapeutic response in IBD. Methods An electronic literature search was performed on 30 January 2018 using MEDLINE, EMBASE and the Cochrane Library. Retrospective, prospective, uncontrolled and controlled studies reporting on biomarkers predicting therapeutic response in paediatric and adult IBD populations were eligible for inclusion. The methodological quality of the included studies was assessed using the QUIPS tool. Due to anticipated heterogeneity and limited data, a qualitative, rather than quantitative, assessment was planned. Results Of the 10 638 citations identified, 92 articles met the inclusion criteria. Several potential DNA, mRNA and protein markers were evaluated as predictive biomarkers. Most studies focused on predicting response to anti‐TNF agents. Substantial between‐study heterogeneity was identified with respect to both the biomarkers studied and the definition of response. None of the included studies received a low risk of bias rating for all six domains. Currently, none of the biomarkers is sufficiently predictive for clinical use. Conclusions The search for predictive biomarkers is still in its infancy and current evidence is limited. Future research efforts should take into account the high patient heterogeneity within prospective trials with objective response assessment. Predictive models will most likely comprise a combination of several molecular markers from integrated omics‐levels and clinical characteristics.

show abstract

Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohnʼs Disease

Abstract: ATI, s-IFX, and s-TNF-α during IFX induction are associated with 12-month clinical outcomes in pediatric CD. Future studies are needed to further define the clinical role of s-TNF-α measurement and to compare the clinical utility of 10 and 14-week ATI and s-IFX levels.

Cited by 38 publications

References 28 publications

Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease

Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease

Diagnosis and management of inflammatory bowel disease in children

Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease—personalised medicine in its infancy

Contact Info

Product

Resources

About